CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies Jul 20, 2023 | Uncategorized
Construction and Immunogenicity Testing of Whole Recombinant Yeast-Based T-Cell Vaccines Jul 10, 2023 | Uncategorized
Intra-Tumor Injection of CAR-Engineered NK Cells Induces Tumor Regression and Protection Against Tumor Re-Challenge Jul 10, 2023 | Uncategorized
An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele Jul 10, 2023 | Uncategorized
High-throughput identification of neoepitopes for the development of patient-specific cancer immunotherapies Jun 29, 2023 | Articles
